Immunogen sequence: MSNGYSTDEN FRYLISCFRA RVKMYIQVEP VLDYLTFLPA EVKEQIQRTV ATSGNMQAVE LLLSTLEKGV WHLGWTREFV EALRRTGSPL AARYMNPELT DLPSPSFENA HDEYLQLLNL LQPTLVDKLL VRDVLDKCME EELLTIEDRN RIAAAENNGN ESGVRELLKR IVQKENWFSA FLNVLRQTGN NELVQELTGS DCSES; Positive Samples: THP-1; Cellular Location: Cytoplasm, Nucleus
DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp and a protein kinase C-activating compound, mezerein. Irreversible reprogramming of melanomas can be achieved by treatment with both these agents; treatment with either agent alone only achieves reversible differentiation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: CADM-140 autoantigen; Clinically amyopathic dermatomyositis autoantigen 140 kDa; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide; Helicard; Helicase with 2 CARD domains; Interferon induced with helicase C domain protein 1; interferon induced, with helicase C domain 1; Interferon-induced helicase C domain-containing protein 1; Interferon-induced with helicase C domain protein 1; MDA-5; melanoma differentiation associated protein-5; melanoma differentiation-associated gene 5; Melanoma differentiation-associated protein 5; Murabutide down-regulated protein; RIG-I-like receptor 2; RLR-2; RNA helicase-DEAD box protein 116
Gene Aliases: 9130009C22Rik; AGS7; Helicard; Hlcd; IDDM19; IFIH1; MDA-5; MDA5; RH116; RLR-2; SGMRT1